Last updated: 2026-09-09 04:51:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Rhythm Pharmaceuticals, Inc. (RYTM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $101.81, with a market capitalization of $7.07B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $74.50 to $122.20. This page covers its latest market performance, valuation, price trends and company information.
$7.07B | |
$100.58 | |
$122.20 | |
$3.04 | |
$102.74 | |
373.14K | |
759.21K | |
-- | |
$122.20 | |
$74.50 | |
-- | |
-- |
Rhythm Pharmaceuticals, Inc. (RYTM) last closed at $102.74 as of 2026-09-08 23:31:00, unchanged from the previous close of $102.74.
During the latest regular trading session, RYTM traded between $3.04 and $122.20, with a volume of 373.14K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Rhythm Pharmaceuticals, Inc. (RYTM) moved from $112.53 to $101.81, representing a decline of 9.53% ($10.72).
The stock traded between $99.04 and $114.75 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 435.97 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 57.3%
RYTM is currently trading at $101.81, placing it 57.3% of the way from its 52-week low of $74.50 to its 52-week high of $122.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 414 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Rhythm Pharmaceuticals, Inc. (RYTM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.